Ex­or­cis­ing Mar­tin Shkre­li’s ghost, Kalo­Bios steps out of Ch. 11 and back in­to the biotech busi­ness

Six months af­ter Mar­tin Shkre­li’s brief, tur­bu­lent role as the con­tro­ver­sial sav­ior of the trou­bled Kalo­Bios end­ed in Chap­ter 11 and near ex­tinc­tion, new CEO Cameron Dur­rant is turn­ing the last page on that chap­ter of pulp fic­tion dra­ma.

This morn­ing Kalo­Bios says it has emerged from bank­rupt­cy with $14 mil­lion in fi­nanc­ing, a new­ly re­or­ga­nized board and a com­plet­ed deal with Sa­vant Ne­glect­ed Dis­eases to de­vel­op ben­znida­zole for the treat­ment of rare cas­es of Cha­gas dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER